Lopitrast

Adult dosage:

• Neurology: Lumber myelography: Iopamidol 370, 6-13 ml,
• Thoraco-cervical myelography: Iopamidol 370, 6-13 ml.
• Urography: Iopamidol 370, 40-80 ml IV up to 1.5 ml/kg in severe renal disease.

Children:

• Usual Dose: 1-2.5 ml/kg
• Other Diagnostic Procedure: Contrast enhancement in CT scanning: Iopamidol 370, 0.5-2.0 ml/kg

Angiography: Cerebral angiography: Iopamidol 370, 6-13 ml

Selective coronary arteriography: Iopamidol 370, 4-8 ml/artery

Peripheral arteriography: Iopamidol 370, 20-50 ml

Venography: Iopamidol 370, 24-60 ml

Angiocardiography: Iopamidol 370, 30-80 ml

Left ventriculography: Iopamidol 370, 30-80 ml

Percutaneous transfemoral or renal arteriography: Iopamidol 370, 30 ml

Selective renal arteriography: Iopamidol 370, 5-10 ml

Hepatic angiography: Iopamidol 370, 70 ml

Coeliac angiography: Iopamidol 370, 40-70 ml

Superior mesenteric angiography: Iopamidol 370, 25-50 ml

Inferior mesenteric angiography: Iopamidol 370, 5-30 ml

Digital subtraction angiography: 30-50 ml (10-20 ml/sec) of Iopamidol 370, IV 25 ml (left ventricle), 2-5 ml (coronary arteries) ,15 ml/sec. of Iopamidol 370 i.a for cardiac imaging

Common side effects are arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.

Treatments of an overdose is directed toward the support of all vital functions and prompt institution of symptomatic therapy.

Iopamidol, an organic Iodine compound and used as a non-ionic water soluble radiographic contrast medium. Iopamidol blocks X-rays as they pass through the body, thereby allowing body structures not containing Iodine to be visualized. The degree of opacity produced by Iopamidol is directly proportional to the total amount of the iodinated contrast agent in the path of the X-rays. The visualization of body structures is dependent upon the distribution and elimination of Iopamidol.

May inhibit blood coagulation. Multiple myeloma or other paraproteinaemia. Sickle-cell disease. Known or suspected phaeochromocytoma (monitor closely). Hyperthyroidism. Ensure adequate hydration. History of a previous sensitivity to a contrast medium, sensitivity to iodine, bronchial asthma, hay fever and food allergy. Monitor patients with CHF. Avoid angiography in patients with homocystinuria. Severe arterial or venous disease. Severe renal impairment, combined renal and hepatic disease or anuria, especially when large doses are used. Pregnancy and lactation.

Contrast medium for diagnostic procedures